OncoMatch/Neuroblastoma/MYCN amplification
NeuroblastomaMYCN amplification Clinical Trials
MYCN amplification is present in approximately 20% of neuroblastoma and defines high-risk disease with rapid progression, poor differentiation, and resistance to standard induction chemotherapy. MYCN drives cell cycle entry through Aurora A kinase (AURKA) stabilization, which is therapeutically targetable. Trials investigate Aurora A inhibitors (alisertib), CDK7/9 inhibitors blocking MYCN transcription, and immunotherapy combinations including anti-GD2 antibodies (dinutuximab) in MYCN-amplified high-risk neuroblastoma.
Top recruiting MYCN amplification Neuroblastoma trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Giselle Sholler
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Giselle Sholler
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Giselle Sholler